Westwood Wealth Management lessened its position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) by 42.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,000 shares of the exchange traded fund’s stock after selling 6,000 shares during the period. Westwood Wealth Management owned approximately 0.68% of ProShares Ultra Nasdaq Biotechnology worth $405,000 at the end of the most recent reporting period.
Separately, Jane Street Group LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock worth $306,000 after purchasing an additional 374 shares in the last quarter.
ProShares Ultra Nasdaq Biotechnology Trading Down 11.2 %
Shares of BIB opened at $40.45 on Friday. The stock’s 50 day moving average is $53.44 and its two-hundred day moving average is $56.57. ProShares Ultra Nasdaq Biotechnology has a twelve month low of $40.37 and a twelve month high of $69.56. The firm has a market capitalization of $44.90 million, a PE ratio of 19.79 and a beta of 1.49.
ProShares Ultra Nasdaq Biotechnology Cuts Dividend
ProShares Ultra Nasdaq Biotechnology Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- How to Choose Top Rated Stocks
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- Industrial Products Stocks Investing
- Spotify Stock Eyes Double-Digit UpsideāIs Now the Time to Buy?
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.